Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2021 07:00 ET | Source: Imara, Inc.

Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D.,...
November 04, 2021 16:01 ET | Source: Imara, Inc.

Imara to Webcast Conference Call of Third Quarter 2021 Financial Results and Business Highlights

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
November 04, 2021 09:17 ET | Source: Imara, Inc.

Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021

Tovinontrine (IMR-687) VOC data in patients with sickle cell disease from ongoing Phase 2a open-label extension study and preclinical models of beta-thalassemia to be presented Oral presentation...
September 15, 2021 07:00 ET | Source: Imara, Inc.

Imara to Participate in Upcoming Investor Conferences

BOSTON, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
September 03, 2021 07:00 ET | Source: Imara, Inc.

Imara to Present at Upcoming Investor Conferences

BOSTON, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
August 06, 2021 07:00 ET | Source: Imara, Inc.

Imara Reports Second Quarter 2021 Financial Results and Business Highlights

Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021 Positive IMR-687 data in sickle cell disease presented at...
July 30, 2021 07:00 ET | Source: Imara, Inc.

Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights

BOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
July 13, 2021 22:58 ET | Source: Imara, Inc.

Imara Announces Pricing of Public Offering

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to...
July 13, 2021 16:01 ET | Source: Imara, Inc.

Imara Announces Launch of Proposed Public Offering

BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to...
June 30, 2021 07:00 ET | Source: Imara, Inc.

Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors

BOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...